Sai Parenterals Limited · NSE:SAIPARENT
Sai Parenterals — Q4 FY26 Earnings Presentation
27 slides from Sai Parenterals's earnings presentation, May 26, 2026
Slide 1: Regulation 30 disclosure cover letter
SAL PARENTERALS To, Date: 26™ May, 2026 The Manager The Manager, BSE Limited NSE Limited, P.J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Sub: Disc
Slide 2: Investor Presentation Q4 & FY26
SAIL PARENTERALS LIMITED SCIENCE > AFFORDABILITY» INNOVATION INVESTOR PRESENTATION Q4 & FY26 MAY 2026
Slide 3: Safe harbour
Safe harbour SAI PARENTERAIS| IMITTED This presentation and the accompanying slides (the “Presentation”), which have been prepared SAl Parenteral's Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or
Slide 4: Quarterly Review
013 QUARTERLY REVIEW
Slide 5: Executive summary
Executive summary Financial highlights Operational highlights Q4FY26 consolidated revenue at 198 crore; Expanded portfolio by 93 dossiers in FY26, EBITDA at %29 crore, reflecting first full-quarter including 88 regulated/emerging market filings and consolidation of Noumed 5 TGA Australia dossiers th
Slide 6: FY26 standalone financial highlights
FY26 standalone financial highlights REVENUE (Z CRORE) EBITDA PAT 162 124 FY25 FY26 FY25 FY26 EBITDA PAT ®Cr) 27 33 @) 10 17 EBITDA PAT margin 8% 10% margin (%) 22% 20% (%) ?1 62 crore ?33 crore %1 7 crore Revenue from operations EBITDA PAT A 31% A 23% A 64% A YoY
Slide 7: FY26 consolidated financial highlights
FY26 consolidated* financial highlights SATI REVENUE (Z CRORE) EBITDA PAT 381 198 I Q4FY26 FY26 Q4FY26 FY26 EBITDA Cr) 29 47 PAT e 13 14 QaFY26 Y26 Margin (%) 24% 12% Margin (%) 9% 1% ?381 crore 347 crore 214 crore Revenue from operations EBITDA PAT * Consolidated financials include wholly owned sub
Slide 8: Company Overview
wy ~ r F | E 4 ‘ me ‘es = cae ' 7 . | Ny MULL = 2 Sige id I < EAS \ 7 y j COMPANY OVERVIEW
Slide 9: Overview
Overview SATI Parenteral’s Limited is a diversified global pharmaceutical formulations company with capabilities in research, development and manufacturing Diversified business model Focus on Global CDMO platform - Revenue mix is diversified across branded generics formulations and - Preferred CDMO
Slide 10: Overview
Overview Injectable capabilities Regulated market approved facilities - Focus on critical care injectables and penicillin-based - Capex infusion at injectable Units I and II for EU-GMP therapies upgradation and capacity expansion - Operating 3 Sterile injectable facilities in Hyderabad (Unit I, IT -
Slide 11: Overview
Overview Noumed, with presence in Australia and New Zealand, R&D capabilities adds scale, synergy and access to global markets - Identification, development and manufacturing of cost-effective generic - Noumed has exclusive long-term supply agreements with Australian formulations across therapeutic
Slide 12: SPL + Noumed = Platform for growth
SPL + Noumed = Platform for growth SPL NOUMED SYNERGIES Commercial Proven track record in « Strong presence in Australian market; « Supports expansion of SPL's global CDMO Ve manufacturing Exclusive long-term supply agreements business into regulated and semi- with Australian pharmacy chains regulat
Slide 13: Overview: facility expansion and upgradation
Overview SAI To meet the growing demand from existing and new customers for specialized products, the Company is actively expanding and upgrading its facilities: Manufacturing Facility Pre- Post- Pre-upgradation Post-upgradation Expected expansion expansion accreditations accreditations date of inst
Slide 14: Our journey so far
Our journey so far Completed IPO in March 2026 Incorporation of SAI Parenteral’s « Acquired PICS Approved Acquired Revat Laboratories Pvt with a primary fund raise of Revat Laboratories acquisition of Cephalosporin Plant (Unit IV) Ltd as a wholly owned subsidiary 285 crore Pvt Ltd by current 100% Eq
Slide 15: Investment Highlights
NINSN[€11N
Slide 16: Diversified branded generic formulations player with an established track record
Diversified branded generic formulations player with an established track record Since 2016, SAI has grown its revenue and diversified across business verticals, geographical markets, and product Business model Products Markets « Indian business focused on branded generic - Manufacturing capabilitie
Slide 17: Strategically located & globally accredited manufacturing facilities
Strategically located & globally accredited manufacturing facilities SAI PARENTERALS LTMITED Particulars SAI Unit I SAI Unit II SAI Unit IIT SAI Unit IV Revat Noumed* Plant location Jeedimetla, Jeedimetla, Bhongir, Telangana Bollaram, Telangana Ongole, Andhra Adelaide, Australia Telangana Telangana
Slide 18: Track record of value-accretive acquisitions
Track record of value-accretive acquisitions SAI Name of entity Fiscal year of Consideration Acquisition rationale acquisition (inXCr) Unit III — TGA Australia approved facility, 2022 2 To expand footprint in regulated markets and enhance manufacturing Bhongir, Hyderabad capacity* Unit IV — PICs app
Slide 19: CDMO business and IP portfolio
Ll Scale-up of CDMO business post Intellectual Property portfolio acquisition of two regulatory approved supporting our CDMO operations SAl is an end-to-end CDMO player plants — expanding through CDMO with expanding global reach and « 506 product registrations in regulatory contracts across regulate
Slide 20: Experienced Promoters and Senior Management
Experienced Promoters and Senior Management SAI PARENTERALS LTMITED Exceptional management team with more than three decades of experience in the pharmaceutical industry Anil KK Vijitha Gorrepati Mark Thulborne Jo-Maree Delac Managing Director Whole-time Director Managing Director Director Sai Paren
Slide 21: Experienced Promoters and Senior Management
Experienced Promoters and Senior Management SAI PARENTERALS LTMITED D B Venkoji Prakash Gurumoorthy Kamma Anil Kumar Shivali Aggarwal Head Corporate- Quality Assurance Company Secretary and the Compliance Chief Executive Officer Chief Financial Officer Sai Parenteral’s Limited Officer Sai Parenteral
Slide 22: Our Strategy
— Pa es ——— s - a | elles = ~ | os X = ie “iy a t pao Z F \ y _ i | Mic SH j - — i ! } ‘ . l : £4] i 7E| i on | lee Se?) ee a | 5 - | | ae OUR STRATEGY
Slide 23: Key Strategies
Key Strategies . Expansion info global injectable formulations market . Capitalize on CDMO opportunity by leveraging our commercial manufacturing with enhanced R&D competences . Strengthening our presence in regulated markets through the upcoming manufacturing facility at Adelaide, Australia . Focus
Slide 24: Usage of IPO proceeds
Usage of IPO proceeds SAI PARENTERALS LIMITED L4 285 Cr IPO gross proceeds* Amount to be funded from net Particulars Sroceeds (% Cr Capacity expansion and upgradation of manufacturing facilities 111 Establishment of a new R&D Centre 18 Repayment / prepayment of certain outstanding institutional borr
Slide 25: Annexure
| suuuiim (g | gy y / 5. nom |\ “" , Annexure
Slide 26: Corporate Structure
Corporate Structure SAI SATI PARENTERALS LIMITED Group Holding Company based in India Houses branded generic formulations & CDMO products and services business Revat Laboratories Private Sai Parenterals Pte Limited SP Analytics Private Limited Limited Singapore-based - Holding company for facilitati
Slide 27: Thank You
THANK YOU For further information contact: Investor relations ir@saiparenterals.com